Oct 13, 2025
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
Oct 09, 2025
Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
May 20, 2025
Lupin and Honeywell Move Forward Jointly with Plans for HFO Technology in Inhalers
Mar 21, 2025
Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery
Oct 28, 2024
Lupin to focus on the development of inhalers with near-zero global warming potential propellants
Jul 15, 2024
Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC
Aug 14, 2020
Lupin Presents Phase 3 Data for Solosec® (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis
Jun 11, 2020
Lupin Pharmaceuticals and PlushCare Expand Access to Bacterial Vaginosis (BV) Treatment to Help Meet Patient Needs During COVID-19 Pandemic
Jun 09, 2020
Ceek and Lupin Sign a Marketing Agreement to Improve OB/GYN and Patient Exam Experience with the Nella® Products
Jun 09, 2020
Lupin Signs Marketing Agreement With Ceek for Women's Health Products to Improve OB/GYN and Patient Exam Experience
Jun 04, 2020
Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept
May 04, 2020
Lupin Announces Positive Topline Results From its Phase 3 Study of Single-Dose Solosec® (secnidazole) for the Treatment of Trichomoniasis
Apr 22, 2020
Lupin Announces SOLOSEC® (secnidazole) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.
Apr 06, 2020
The global anti-rheumatics market is anticipated to record a CAGR of 2.32% during the projected period of 2020-2028
Mar 27, 2020
Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept
Sep 12, 2019
Global Neurology Market Research Overview 2019: Competitive Environment, Regulations, Epidemiology, M&As, Pipeline Drugs
Jun 06, 2019
Visiongain Report Provides Critical Market-led Data on the $36bn Dermatological Drugs Market
Dec 06, 2018
ZAXINE® (rifaximin) - Now Indicated in Canada for Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)1,2
Dec 04, 2018
Global Opioids Drug Market Forecast 2019-2027
Sep 06, 2018
LEUKOCARE and Xellia Pharmaceuticals Partner to Discover Innovative Formulations for the Development of Value-added Anti-infective Therapies